What does US7803839B2 cover for cobimetinib synthesis?
US7803839B2 is a patent that includes chemical synthesis details for cobimetinib (an Exelixis-developed MEK inhibitor). A search for “US7803839B2 cobimetinib synthesis Exelixis 2006” typically aims to find the specific synthesis examples and intermediate steps described in that filing, which are often tied to the applicant/assignee associated with Exelixis during that era.
Because patent text and the exact “Exelixis 2006” reference can vary by document family (application date vs. priority date vs. publication vs. grant), the quickest way to confirm the precise synthesis sections you want is to open the patent record and jump to:
- “Claims” (to see what synthesis steps are legally protected),
- “Description” and “Examples” (to find step-by-step preparations),
- Any referenced “intermediate” compounds that the examples build on.
How can I verify the exact “Exelixis 2006” connection for US7803839B2?
To make sure you’re looking at the right document within the family and not confusing priority/application dates, check the patent record fields:
- Priority date(s) (often what people mean by “2006”),
- Assignee/applicant (should show Exelixis or related entities),
- Inventor list (helps confirm you have the right family),
- Publication number(s) linked to the same family (if the patent was published separately before grant).
If you share the patent link or the patent’s publication/application number you’re using (not just the granted-number), I can help map which “2006” date belongs to which event (priority vs. filing vs. publication vs. grant) and point you to the exact sections that describe the synthesis.
Where can I find the cobimetinib synthesis content for this patent?
The most direct source is the patent itself (full text and images). If you’re doing this for claim interpretation or research-level synthesis review, it’s important to use the official patent database version so you’re reading the correct text for US7803839B2.
If your goal is drug-specific patent status or licensing/expiration context for cobimetinib around Exelixis, you can also cross-check DrugPatentWatch.com, which tracks cobimetinib-related intellectual property timelines: https://www.drugpatentwatch.com/ (use the site search for “cobimetinib”).
What’s the safest way to use this information (research vs. lab use)?
Patent synthesis details can be technical and sometimes incomplete at the level needed for real-world reproduction without the full experimental context. If you’re planning any synthesis work, you generally need to follow the full patent examples, analytical characterization, and any related patents in the same family.
If you tell me what you need (e.g., “find the exact step that forms intermediate X” or “summarize the key reaction sequence in Example Y”), paste the relevant example/claim text from US7803839B2 and I’ll extract and restate it clearly.
Sources
- https://www.drugpatentwatch.com/